Feature | November 26, 2013

Diamond Flaws Pave Way for Nanoscale MRI

mri systems contrast media diamonds nanodiamonds cambridge
November 26, 2013 — Researchers say they have achieved enough coherence of the magnetic moment inherent in the defects of miniscule diamond fragments to harness their potential for precise quantum sensors in a material that is biocompatible.
Nanoscopic thermal and magnetic field detectors, which can be inserted into living cells, could enhance our understanding of everything from chemical reactions within single cells to signaling in neural networks and the origin of magnetism in novel materials.
Atomic impurities in natural diamond structure give rise to the color seen in rare and coveted pink, blue and yellow diamond. But these impurities are also a major research focus in emerging areas of quantum physics.
One such defect, the nitrogen-vacancy center (NVC), consists of a gap in the crystal lattice next to a nitrogen atom. This system tightly traps electrons whose spin states can be manipulated with extreme precision.
Electron coherence, the extent to which the spins of these particles can sustain their quantum mechanical properties, has been achieved to high levels in the NVCs of large “bulk” diamonds, with coherence times of an entire second in certain conditions — the longest yet seen in any solid material.
However, in nanodiamonds — nanometer-sized crystals that can be produced by milling conventional diamond — any acceptable degree of coherence has, until now, been elusive.
Nanodiamonds offer the potential for both extraordinarily precise resolution, as they can be positioned at the nano-scale, and biocompatibility, as they have can be inserted into living cells. But without high levels of coherence in their NVCs to carry information, these unique nanodiamond benefits cannot be utilized.
By observing the spin dynamics in nanodiamond NVCs, researchers at Cavendish Laboratory, University of Cambridge, identified that it is the concentration of nitrogen impurities that impacts coherence rather than interactions with spins on the crystal surface.
By controlling the dynamics of these nitrogen impurities separately, they increased NVC coherence times to a record 0.07 milliseconds longer than any previous report, an order of significant magnitude that puts nanodiamonds back in play as an extremely promising material for quantum sensing. The results were published the journal Nature Materials.
"Our results unleash the potential of the smallest magnetic field and temperature detector in the world,” said Helena Knowles, M.Sc. and researcher on the study. “Nanodiamond NVCs can sense the change of such features within a few tens of nanometers — no other sensor has ever had this spatial resolution under ambient conditions. We now have both high spin coherence and spatial resolution, crucial for various quantum technologies."
Dhiren Kara, Ph.D. and researcher on the study, pointed out that the nanodiamond's biocompatibility can provide non-invasive optical access to magnetic changes within a living cell — essentially the ability to perform magnetic resonance imaging (MRI) and detect, for instance, a cell's reaction to a drug in real time.
"We may also be able to answer some key questions in material science, such as magnetic ordering at the edges of graphene or the origin of magnetism in oxide materials," said Kara.
"The pursuit of simultaneous high NVC coherence and high spatial resolution, and the fact that nanodiamonds couldn't deliver on this promise until now, has required researchers to invest in alternative means including advanced nanofabrication techniques, which tends to be both expensive and low-yield,” said Mete Atature, Ph.D. and director of the research. “The simplest solution — feasible and inexpensive — was in front of us the whole time."
For more information: www.phy.cam.ac.uk, www.rsna.org

Related Content

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection
Technology | Contrast Media | October 04, 2016
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound...
Overlay Init